{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000055","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.492278+00:00","generated_at":"2026-06-01T04:07:23.901706+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Keros reports durable transfusion independence in Phase 2 MDS trial; plans registrational Phase 3","bullets":["Overall erythroid response 55.6% (45/81) in modified ITT patients; 41.3% (26/63) of TI-evaluable achieved ≥8-week transfusion independence.","Median duration of TI not reached; 42.3% (11/26) of TI responders had responses >1 year, all ongoing as of April 3, 2024.","In MF Phase 2, 60.6% (20/33) of transfusion-dependent patients had reduced transfusion burden; 52.9% (9/17) with large spleens had volume reductions at Week 24.","Preclinical MF model data shows elritercept promotes erythropoiesis, mitigates anemia, and improves muscle mass/function.","Company plans to initiate a registrational Phase 3 trial in lower-risk MDS following positive FDA feedback."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000055","json":"https://secwatch.observer/filing/0001664710-24-000055.json","markdown":"https://secwatch.observer/filing/0001664710-24-000055.md","text":"https://secwatch.observer/filing/0001664710-24-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000055/0001664710-24-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000055/kros-20240617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:07:23.901706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}